about
Control of RANKL gene expressionAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewNew pharmacological strategies in rheumatic diseasesBiologic therapies and bone loss in rheumatoid arthritis.An African ancestry-specific allele of CTLA4 confers protection against rheumatoid arthritis in African Americans.Bone remodelling markers in rheumatoid arthritis.Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment.Osteoclasts: more than 'bone eaters'.Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)The emerging field of osteoimmunologyOsteoclast activated FoxP3+ CD8+ T-cells suppress bone resorption in vitro.CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production.T-cells and B-cells in osteoporosisBlockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis.Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection.Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors.Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model.Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct mannersTrauma-induced heterotopic bone formation and the role of the immune system: A reviewTranslating co-stimulation blockade into clinical practice.The Interplay between the bone and the immune systemOsteoimmunology in rheumatic diseasesHow antirheumatic drugs protect joints from damage in rheumatoid arthritis.The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate.CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model.Self in vivo production of a synthetic biological drug CTLA4Ig using a minicircle vector.Osteoporosis in inflammatory joint diseases.Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.Can bone loss in rheumatoid arthritis be prevented?Osteoimmunology: a brief introductionCTLA-4 blockade in the treatment of rheumatoid arthritis: an update.Emerging drugs for psoriatic arthritis.Memory B Cells and Response to Abatacept in Rheumatoid Arthritis.The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.Physiological and pathophysiological bone turnover - role of the immune system.Osteoimmunology: memorandum for rheumatologists.T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway.T Regulatory Cells in Bone Remodelling.A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.
P2860
Q24619669-41CE4D49-22D4-4118-BB3D-AC8C198831E1Q26774874-EB25A98C-BDA3-46F9-83E5-E2A0742207ECQ28073763-3D0FB88C-C48B-4F1D-B038-822CF8A3AF48Q30243911-02F3EC14-DD48-4428-BC00-2EDF2A3F2D37Q33419824-B49E063B-971C-4134-9089-1CA761D1D52CQ33563068-8BFE2AB0-1AF9-4EE5-A4BF-F4942FE6D98EQ33896725-DB2E2A56-DFC1-4692-9EB6-F2DF004EC554Q33993757-51E3C336-7606-4B5A-A014-CD4391FE3527Q34081877-F04D49CF-2514-49D4-A8E3-993CAEC459BFQ34108110-E1B5A157-5974-4F47-834C-E9009F7EAA0AQ34305347-5890CED2-2A49-4475-BCD1-085C2F3BF390Q34413292-F4D7EAE3-CC7D-4B06-8A5F-16A32F751626Q35035665-3EA8261F-620C-4D27-9849-D90EBAD6995BQ35222786-A3C4D9B9-D8D4-4030-A90F-68BDDE40EC0EQ35572441-1837FC86-C5F6-4FA2-8240-15C2FFB8F617Q35617591-AFB31685-B941-4D78-8C1E-5C2CCC169D43Q35986133-9C48183A-D2C8-4B4B-99DC-0AFB4D5EAB84Q36018275-23305BDE-904B-4736-9ABB-3F61C99CF99FQ36395829-BC4E268E-A8AD-47D3-8834-F80FAD269431Q36972500-6738D5EE-A69E-411A-BEE3-573095A53F82Q37052226-05B040EF-F8A3-4A6E-A667-526C328A907EQ37207025-802A32BE-0256-43A6-B680-9F3EE7FEC575Q37281049-F591385B-8DC9-4F99-A77F-CAAFDB50B8D6Q37287589-AACD6D9A-97E3-4081-AA53-A3E23809FCA0Q37690607-5248A14C-4C05-4037-8E35-C30722D44D23Q37715449-3AE8E2EF-F1E6-47CD-93DE-9B7B2DBF13CAQ37738491-144E4E8C-41A6-4D55-83C8-8A276E929963Q37765505-8360253B-EF9C-46C9-8FFC-DD1BD404972DQ37801555-5D9E6C98-83F2-4BA0-B5E1-E7A6A9390A24Q38115190-35C04278-7352-42CE-9653-1283A9DEBD8DQ38134720-738AE174-71D5-43AC-9650-D4D2C8FC32E7Q38672568-EDE6CACD-0D18-404B-8ECE-AD393F199C72Q38710642-7CBD4B87-5F51-4BB6-BA64-0ED470AE8486Q38801224-589DE63B-F484-49AB-B1B9-9D57E49BEB17Q38831693-82914EB8-533B-4F1D-BFFC-DF6A2BB775A8Q38867785-54E5D21D-3349-403D-B2E2-AF05831F6EDDQ38960189-5ECBE2E8-C1D9-435A-8830-E061383E0075Q39196616-BAF02012-C606-427E-8055-1D47ACDE102DQ39255811-6DFC5BBA-4FE3-4722-83C6-2D8804C025B2Q39483693-9FEADD82-3D6F-435D-9E3B-070D79891998
P2860
description
im November 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 18 January 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2008
@uk
name
CTLA-4 directly inhibits osteoclast formation
@en
CTLA-4 directly inhibits osteoclast formation
@nl
type
label
CTLA-4 directly inhibits osteoclast formation
@en
CTLA-4 directly inhibits osteoclast formation
@nl
prefLabel
CTLA-4 directly inhibits osteoclast formation
@en
CTLA-4 directly inhibits osteoclast formation
@nl
P2093
P356
P1476
CTLA-4 directly inhibits osteoclast formation
@en
P2093
P304
P356
10.1136/ARD.2007.080713
P407
P577
2008-01-18T00:00:00Z